NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
46 trialsNCT07455903 2026-03-06
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05498272 2026-01-23
NePtune
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT06922318 2025-09-17
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT04181203 2025-07-30
CARLHA-2
UNICANCER
Phase 3 Active not recruiting
NCT00667069 2025-06-05
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
UNICANCER
Phase 3 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT02346253 2025-04-03
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
Phase NA Active not recruiting
NCT02685397 2024-12-04
PCS IX
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2/3 Active not recruiting
NCT06282588 2024-02-28
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT03899077 2024-02-07
SAVE
Cancer Research Antwerp
Phase 2 Unknown
NCT05851547 2024-01-05
DEFINE
Ottawa Hospital Research Institute
Phase 2 Recruiting
NCT04242017 2023-12-13
LOBSTER
Universitaire Ziekenhuizen KU Leuven
Phase 2/3 Recruiting
NCT05781217 2023-11-18
URONCOR 06-24
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase 3 Recruiting
NCT05019846 2023-04-18
SPA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Recruiting
NCT04869371 2022-12-29
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05557604 2022-09-28
STUNNIN
Regina Elena Cancer Institute
Phase 2 Recruiting
NCT05212857 2022-03-16
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Fudan University
Phase 2 Unknown
NCT04248621 2021-07-29
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Wonju Severance Christian Hospital
Phase 4 Unknown
NCT00104741 2021-02-21
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
UNICANCER
Phase 3 Completed
NCT01753297 2020-12-09
PRIORITI
Ipsen
Phase 4 Completed
NCT02168062 2020-07-23
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02742675 2020-07-07
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
Fudan University
Phase 2 Unknown
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT01715129 2019-12-09
DKP 3M SC
Ipsen
Phase 3 Completed
NCT00415246 2019-11-22
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
Ipsen
Phase 3 Terminated
NCT00444639 2019-11-22
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
Ipsen
Phase 2 Terminated
NCT01374087 2019-09-18
ANABRAQ
Ipsen
Phase 2 Terminated
NCT01257425 2019-02-08
PAMIS
Ipsen
Phase 2 Completed
NCT01020448 2019-01-30
Triptocare
Ipsen
Phase 3 Completed
NCT00003734 2016-07-21
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT02102646 2015-10-28
MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
Herlev Hospital
Phase 4 Completed
NCT01656161 2015-09-15
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT00751790 2014-07-25
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed